Our finding that growth of tumor-propagating cells in this system are MYCN-dependent, and to some extent can be forced to differentiate by targeted inhibition of MYCN, resulting in regression of tumors highlights the therapeutic potential of MYCN-targeted treatment approaches for patients with aggressive MB. Here, MYCN is linked to neoplasm.